Last reviewed · How we verify
Postop hydromorphone IV
Hydromorphone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and sedation.
Hydromorphone is a mu-opioid receptor agonist that binds to opioid receptors in the central nervous system to produce analgesia and sedation. Used for Postoperative pain management.
At a glance
| Generic name | Postop hydromorphone IV |
|---|---|
| Also known as | Dilaudid |
| Sponsor | AdventHealth |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydromorphone activates mu-opioid receptors in the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. This results in potent analgesia suitable for moderate to severe acute pain. The IV formulation provides rapid onset of action, making it appropriate for postoperative pain management in hospital settings.
Approved indications
- Postoperative pain management
Common side effects
- Respiratory depression
- Sedation
- Nausea
- Vomiting
- Dizziness
- Constipation
- Hypotension
Key clinical trials
- Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery (PHASE4)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies (NA)
- The Impact of Intraoperative Methadone on Postoperative Opioid Use (PHASE3)
- Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement) (PHASE4)
- NSAID Use After Robotic Partial Nephrectomy (PHASE2)
- Pain Management Study (PHASE4)
- IV vs Epidural Opioids + Epidural Local Anesthetic for Laparotomy Analgesia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Postop hydromorphone IV CI brief — competitive landscape report
- Postop hydromorphone IV updates RSS · CI watch RSS
- AdventHealth portfolio CI